Cardiovascular Diseases

The Division of University Cardiology at Ospedale Galeazzi S.p.A. is advancing research on heart‑related conditions by testing innovative therapies aimed at reducing plaque buildup and valve calcification.

  • Evaluation of inclisiran added to statin therapy to lower coronary atheroma volume.
  • Assessment of pelacarsen for slowing progression of calcific aortic valve stenosis.
  • Investigation of olpasiran on non‑calcified plaque volume using coronary CT angiography.
  • Study of SGLT2 inhibitors to stabilize coronary atherosclerosis after acute myocardial infarction.

These trials reflect the hospital’s commitment to improving cardiovascular outcomes for patients across Europe.

Hemic and Lymphatic Diseases

Research at the site includes strategies to prevent blood‑clot related complications, particularly after orthopedic surgery, aiming to enhance safety for at‑risk individuals.

  • Comparison of IV REGN7508 versus aspirin for preventing symptomatic venous thromboembolism after total knee arthroplasty.
  • Evaluation of clot‑related biomarkers in patients with a history of venous thromboembolism.
  • Long‑term safety monitoring of anticoagulant regimens in post‑surgical populations.

The work supports Ospedale Galeazzi S.p.A.’s role in reducing thrombotic risk for surgical patients.

Immune System Diseases

The cardiology division collaborates on studies targeting autoimmune conditions, focusing on symptom relief and disease‑modifying effects of novel agents.

  • Effect of HZN-1116 on systemic manifestations and patient‑reported symptoms of Sjögren’s Syndrome.
  • Long‑term safety and tolerability of subcutaneous secukinumab in polymyalgia rheumatica.
  • Impact of Baricitinib on synovial inflammation in calcium pyrophosphate deposition disease.

These investigations aim to broaden therapeutic options for patients with challenging immune‑mediated disorders.

Musculoskeletal Diseases

A variety of trials address joint degeneration and chronic pain, testing regenerative approaches and analgesic medications to improve mobility and quality of life.

  • Implantation of tissue‑engineered nasal cartilage (N‑TEC) versus standard care for patellofemoral osteoarthritis.
  • Analgesic efficacy of DFL24412 compared with ketoprofen lysine salt in chronic low back pain.
  • Weight loss and pain reduction outcomes with NNC0487‑0111 in overweight adults with knee osteoarthritis.
  • Evaluation of Baricitinib on synovial tissue inflammation in calcium pyrophosphate deposition disease.

The site’s multidisciplinary approach seeks to restore function for patients suffering from musculoskeletal ailments.

Nutritional and Metabolic Diseases

Studies at the hospital explore metabolic risk factors and bone health, linking obesity, diabetes, and osteoporosis with cardiovascular complications.

  • Effect of SGLT2 inhibitors on coronary atherosclerosis progression after myocardial infarction in diabetic patients.
  • Comparison of Romosozumab versus denosumab on coronary atherosclerotic damage in post‑menopausal osteoporosis.
  • Weight‑management and pain‑relief trial using NNC0487‑0111 for participants with excess body weight and knee osteoarthritis.
  • Investigation of metabolic contributors to calcific aortic valve stenosis progression.

These efforts underline Ospedale Galeazzi S.p.A.’s dedication to integrating metabolic health with cardiovascular care.